Determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question. Biomarkers have been shown to predict therapy outcome in various types of cancer patients. This talk will focus on the development and clinical applications of circulating RNA and DNA-based liquid biopsy tests in biomarker-driven clinical trials.

Learning Objectives:

1. Learn about the latest development of predictive and prognostic biomarkers, the clinical utility of biomarkers in clinical studies, and their potential as companion diagnostics
2. The gap between biomarkers and precision medicine (targeted therapy, immuno-oncology, and cell therapy)